Is Capricor Therapeutics Inc (CAPR) overvalued? · $1.62B cap
Capricor Therapeutics Inc (CAPR) is a biotechnology company listed on NASDAQ.
This page asks whether Capricor Therapeutics Inc (CAPR) looks expensive on cached numbers — not a short thesis.
Latest reported CAPR revenue for 2025-12-31 was $0. Net income was -$105.0M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. CAPR currently screens at market cap $1.62B.
CAPR currently screens at market cap $1.62B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CAPR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CAPR stock page for the full model, not this heading.
Not investment advice.